hVIVO PLC reported full-year 2025 results with revenue just under £47 million and a positive EBITDA of over £1 million, exceeding earlier guidance despite a tough macroeconomic environment. The company strengthened its cash position to over £40 million and expanded its service offerings through acquisitions of clinical trial units in Germany and CryoStore in the UK, creating a comprehensive platform for clinical development. While the human challenge trial segment faced challenges due to vaccine market volatility, proposal activity increased 50% year-on-year in early 2026. Looking ahead, hVIVO expects high single-digit revenue growth in 2026, supported by a broader client base and new contracts, including one with Traws Pharma for an influenza human challenge trial.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
